Abstract: This invention provides synthetic .beta.-lactam antibacterial compounds, a process for their preparation and pharmaceutical compositions containing them.The compounds are those of the formula (II): ##STR1## wherein: R.sub.1 is a group such that CO.sub.2 R.sub.1 is a carboxylic acid group or a salt or ester thereof; and R.sub.2 is a phenyl group or a phenyl group substituted by one to four groups selected from lower alkyl, fluorine, chlorine, bromine, CN, NO.sub.2, COR.sub.3, OR.sub.3, SR.sub.3, NH.sub.2, NHCOR.sub.3, NHCO.sub.2 R.sub.3, CO.sub.2 R.sub.3 or CO.sub.2 R.sub.10 where R.sub.3 is lower alkyl, benzyl, fluorobenzyl, chlorobenzyl, bromobenzyl or nitrobenzyl and CO.sub.2 R.sub.10 is carboxyl or a salt thereof, not more than three such groups being selected from fluorine, chlorine, bromine, CN, NO.sub.2, NH.sub.2, COR.sub.3 or CO.sub.2 R.sub.3 and not more than two such groups being selected from CN, NO.sub.2 and NH.sub.2.

Abstract: The present invention relates to an antibacterial composition and to a method for the treatment of infectious diseases caused by pathogenic bacteria employing a phosphonic acid derivative and an antibiotic.

Abstract: It has been found that a novel antibiotic can be obtained by the fermentation of certain strains of Streptomyces olivaceus and related organisms. In addition to being a potent antibiotic this new material which we have designated MM 13902 acts synergistically with penicillins and cephalosporins.

Abstract: It has been found that a novel antibiotic can be obtained by the fermentation of certain strains of Streptomyces olivaceus and related organisms. In addition to being a potent antibiotic this new material which we have designated MM 13902 acts synergistically with penicillins and cephalosporins.

Abstract: An antibacterial synergistic composition consisting essentially of a mixture of a penicillin or cephalosporin derivative of the formula ##STR1## and a penicillin of the formula ##STR2## preferably in association with a pharmaceutical carrier.

Abstract: It has been found that an antibiotic can be obtained by the fermentation of certain strains of Streptomyces olivaceus and related organisms and when pure this antibiotic is an extremely potent inhibitor of many .beta.-lactamases. This antibiotic which we designate MM 4550A may be obtained in substantially pure form by the chromatographic purification of the crude antibacterial complex obtained from the culture medium.

Abstract: An antibacterial composition for medical use comprising 6-[-)-.alpha.-(4-ethyl-2,3-dioxo-1-piperazinylcarbonylamino)phenylacetamid o]penicillanic acid or a pharmaceutically acceptable salt thereof and a .beta.-lactamase-inhibiting penicillin or cephalosporin. The composition exhibits synergistic effect which is much greater than the sum of antibacterial effects of each component used alone.

Abstract: An antibacterial composition, and a method for treating infectious diseases by application of the same to animals, comprising a phosphoric acid derivative of the formula ##STR1## where R is lower alkanoyl, and one of nocardicin A, ampicillin, ticarcillin, or cefazolin, or their pharmaceutically acceptable salts. The combination exhibits synergistic antibacterial activity.

Abstract: Compounds of the formula (II) ##STR1## wherein R.sub.1 is CH.sub.3, CH.sub.2 OH, CHO or CH.sub.2 OCOR.sub.4 wherein R.sub.4 is a hydrocarbon of 1-7 carbon atoms andR.sub.2 is a group of the formula R.sub.3 or COR.sub.3 wherein R.sub.3 is a hydrocarbon of 1-7 carbon atoms optionally inertly substituted by halogen are useful as antibacterial agents and .beta.-lactamase inhibitory agents.

Abstract: .beta.-Lactamase inhibitory and antibacterial compounds of the formula: ##STR1## wherein R is a hydrogen atom or an acyl group and salts and esters thereof, are produced and pharmaceutical compositions containing the same.

Abstract: .beta.-Lactamase inhibitory and antibacterial compounds of the formula: ##STR1## wherein R is a hydrogen atom or an acyl group and salts and esters thereof, procedure for their preparation and pharmaceutical compositions containing the same.

Abstract: Compositions having antibiotic properties containing as antibiotic potentiators peptides of the formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a lower alkyl, lower cycloalkyl, (lower cycloalkyl)-(lower alkyl), aryl or aryl(lower alkyl) group (said group being optionally substituted as the case may require by one or more amino, hydroxy, thio, methylthio, carboxy or guanidino groups so as to form the characterizing group of a naturally occurring L .alpha.-amino acid); R.sup.2 and R.sup.3 each represent the characterizing group of an .alpha.-amino acid of the type normally found in proteins with the proviso that R.sup.3 cannot represent a hydrogen atom when n is zero and R.sup.1 is a hydrogen atom or the phenyl group; R.sup.4 represents a hydroxy or methyl group; n stands for zero, 1, 2 or 3; and single asterisks denote that the configuration at the carbon atom so-marked is L when R.sup.2 or R.sup.

Abstract: Antibacterial synergistic mixture of Nocardicin A and cycloserine or their respective pharmaceutically acceptable salts.

Abstract: Synergistic coccidiocidal combinations comprise two ionophorous fermentation-derived coccidiocides, each of which is administered to poultry in a concentration too low to produce satisfactory coccidiocidal effect alone. Preferred combinations include monensin and A204, monensin and lasalocid, and monensin and A28086.

Abstract: Synergistic coccidiocidal combinations comprise two ionophorous fermentation-derived coccidiocides, each of which is administered to poultry in a concentration too low to produce satisfactory coccidiocidal effect alone. Preferred combinations include monensin and A204, monensin and lasalocid, and monensin and A28086.

Abstract: An enzyme of hydrolytic action, according to the invention, is a neutral protease having the molecular weight of about 37,000, the isoelectric point at pH 8.8, the optimum activity at 40.degree. - 45.degree. C, the stability range in aqueous solutions at pH 6.8 - 8.0, quickly inactivating in said solutions at temperatures above 50.degree. C.The enzymatic preparation containing the enzyme of hydrolytic action in an amount of 50 - 500 PU/g and the metabolites of the strains Streptomyces hygroscopicus.A method for preparing the hydrolytic enzyme, in which the strain Streptomyces hygroscopicus is cultivated on media containing assimilable sources of carbon and nitrogen, inorganic mineral salts, in deep aerobic conditions, with accumulation of the enzyme of hydrolytic action and the metabolites of the said strains in the culture fluid, followed by subsequent isolation of the enzyme.

Abstract: Amoxycillin derivatives, their preparation and injectable compositions containing such derivatives. A preferred composition comprises a mixture of sodium amoxycillin and D-.alpha.-carboxyamino-p-hydroxybenzylpenicillin disodium salt in a 1:1 ratio and a pharmaceutically acceptable carrier. Typically, 0.25 g of a mixture according to the invention is dissolved in about 0.5-5 ml of sterile water or saline to form an injectable composition.

Abstract: A mutant strain of Micromonospora purpurea herein designated M. purpurea JI-20 elaborates an antibiotic complex comprising gentamicin and at least two novel antibiotic substances namely Antibiotic JI-20A and Antibiotic JI-20B. The so-produced antibiotics have an adverse effect upon the growth of gram-positive and gram-negative bacteria.

Abstract: A film or sheet material having antibacterial and antifungal activities is obtained by mixing a thermoplastic resin with 2-(4'-thiazolyl)-benzimidazole and N-(fluorodichloromethylthio)-phthalimide, and shaping the resulting mixture, or, alternatively, by coating a base film or sheet material on one side or both sides with a coating material containing a mixture of 2-(4'-thiazolyl)-benzimidazole and N-(fluorodichloromethylthio)-phthalimide, a mixture of 2-(4'-thiazolyl)-benzimidazole and N-dimethyl-N'-phenyl-N'-(fluorodichloromethylthio)-sulfamide, or a mixture of N-(fluorodichloromethylthio)-phthalimide and N-dimethyl-N'-phenyl-N'-(fluorodichloromethylthio)-sulfamide.

Abstract: This disclosure deals with novel man-induced molds of the pencillium type found, however, to have both gram positive and gram negative antimicrobial effects, which effects have further been discovered to be synergistically enhanced in mixed culture.

Abstract: This invention provides a lubricating compound for the fitting of crowns, bridges and other prosthodontic restorations as used in prosthodontic dentistry. This compound in a preferred embodiment has a base which comprises 90 or more percent of the compound. A coloring agent which may be zinc oxide is five percent or less of the compound while small percentages of a bacteriostatic agent and an anti-inflammatory agent make up the rest of the compound. The compound is preferably readily washed from the prepared teeth and restoration after a try-in of the unfinished crown, bridge or other prosthodontic restoration has been done. This lubricant provides a new testing technique to be employed for the duration of the trial period of the restoration.

Abstract: Compositions containing a mixture of 2-isopropoxynaphth-1-yl penicillin and cephaloridine or cephalothin have been found to show enhanced activity against certain clinically important bacteria.

Abstract: Compositions containing a mixture of 2-isopropoxynaphth-1-yl penicillin and cephaloridine or cephalothin have been found to show enhanced activity against certain clinically important bacteria.

Abstract: The antibiotic primycin synergizes the effect of other antibiotics when used together therewith in amounts such that the primycin constitutes 5 to 50% by weight of the total antibiotic content.

Abstract: Pathogens are controlled by concomitant contact with a phosphonomycin antibiotic and a bacteriostatic chemotherapeutic compound by separate or simultaneous administration. The combined action is especially advantageous in contacting resistant microorganisms and other microorganisms which are oridinarily not controlled by contact with the individual chemotherapeutic agents.